🔎 Trials Near Me

Akèy › Kansè ovè › New Jersey

Etid klinik pou Kansè ovè nan New Jersey

40 etid pou Kansè ovè ap chèche patisipan nan sit nan New Jersey.

Vil nan New Jersey

Tèks ofisyèl etid la (Anglè)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Hunterdon Medical Center, Flemington
  • Monmouth Medical Center Southern Campus, Lakewood
  • Cooperman Barnabas Medical Center, Livingston
  • ak 6 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • START New Jersey, East Brunswick
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • John Theurer Cancer Center at Hackensack UMC, Hackensack
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, New Brunswick
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • John Theurer Cancer Center /ID# 275756, Hackensack
  • Rutgers Cancer Institute of New Jersey /ID# 274358, New Brunswick
  • Holy Name Medical Center /ID# 276240, Teaneck
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, East Brunswick
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Md Anderson Cancer Center At Cooper /ID# 278390, Camden
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845

A Study of Isoquercetin in People With Ovarian Cancer

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07303894

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Ap rekriteFaz 2
Laj 18 a 99 · Fanm · Mizajou Sep 15, 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Maimonides Medical Center, Short Hills
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • START New Jersey East Brunswick, East Brunswick
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Astera Cancer Care, East Brunswick
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • START - New Jersey, East Brunswick
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081), Hackensack
  • Rutgers Cancer Institute of New Jersey ( Site 0071), New Brunswick
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06824467

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

  • Start Njeb, East Brunswick
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 1, 2026 · NCT07736937

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • John Theurer Cancer Ctr at Hackensack Univ. Med Ctr., Hackensack
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Monmouth, Middletown
  • Memorial Sloan Kettering Bergen, Montvale
  • ak 1 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Hackensack
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • John Theurer Cancer Center, Hackensack
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooper Hospital University Medical Center, Camden
  • Jersey City Medical Center, Jersey City
  • ak 12 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Summit Medical Group, Berkeley Heights
  • Cooper Hospital University Medical Center, Camden
  • ak 9 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • MD Anderson Cancer Center at Cooper- Two Cooper Plaza, Camden
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Valley Health System, Paramus
  • Holy Name, Teaneck
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Overlook Medical Center, Summit
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jul 1, 2026 · NCT05429970

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

  • GSK Investigational Site, Morristown
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04641247

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

  • Carol G. Simon Cancer Center / Atlantic Health, Morristown
Ap rekriteVolontè an sante akeyi
Laj 50 a 74 · Fanm · Mizajou May 6, 2026 · NCT00539162

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  • Holy Name Medical Center, Teaneck
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Apr 16, 2026 · NCT05659381

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

  • Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT06290193

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Hackensack University Medical Center, Hackensack
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06778863

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 11, 2026 · NCT06623396

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • Rutgers Cancer Institute, New Brunswick
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, New Brunswick
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

  • Exelixis Clinical Site #9, New Brunswick
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 5, 2025 · NCT05932862

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.